HeartSciences (NASDAQ:HSCS) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of HeartSciences (NASDAQ:HSCS) from a sell rating to a hold rating in a research note issued to investors on Sunday,Wall Street Zen reports.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of HeartSciences in a research note on Wednesday, June 24th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $8.00.

HeartSciences Price Performance

HeartSciences stock opened at $4.61 on Friday. HeartSciences has a 12-month low of $1.63 and a 12-month high of $5.25. The stock has a market capitalization of $22.13 million, a P/E ratio of -1.43 and a beta of 1.85. The firm’s 50-day moving average is $2.89 and its two-hundred day moving average is $2.46.

HeartSciences (NASDAQ:HSCS) last posted its quarterly earnings data on Monday, September 14th. The company reported ($0.86) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.14). The firm had revenue of $0.00 million for the quarter, compared to analyst estimates of $0.10 million. As a group, analysts forecast that HeartSciences will post -2.99 EPS for the current year.

About HeartSciences

HeartSciences, Inc is a medical technology company focused on improving the detection and management of cardiovascular disease. The company develops electrocardiography (ECG) technologies intended to provide clinicians with additional information about cardiac function using a test that is widely available in healthcare settings.

Its principal technology is the MyoVista wavECG system, which applies proprietary signal-processing methods, including wavelet analysis, to standard 12-lead ECG data.